Phio Pharmaceuticals Corp. (PHIO) NASDAQ
1.29
+0.065(+5.33%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
1.29
+0.065(+5.33%)
Currency In USD
| Previous Close | 1.22 |
| Open | 1.22 |
| Day High | 1.31 |
| Day Low | 1.21 |
| 52-Week High | 4.19 |
| 52-Week Low | 0.81 |
| Volume | 537,717.65 |
| Average Volume | 3.95M |
| Market Cap | 14.93M |
| PE | -0.89 |
| EPS | -1.45 |
| Moving Average 50 Days | 1.13 |
| Moving Average 200 Days | 1.76 |
| Change | 0.07 |
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
Newsfile
Mar 10, 2026 11:00 AM GMT
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing of Prussia, Pennsylvania--(News
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894
Newsfile
Feb 19, 2026 12:00 PM GMT
Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania--(Newsfile Corp
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
Newsfile
Feb 10, 2026 12:00 PM GMT
Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation